Management of glycemia

Glyco680mg has been formulated from a selection of polyphenols from olive and blackcurrant, carefully chosen through a clinical screening for their ability to manage post-prandial glycemia. 

The formulation has been enriched in essential minerals such as zinc and chromium, and a white kidney bean extract standardised for its amylase inhibition capacity at 500 mg per day. Each of the ingredients chosen in the formulation of Glyco680mg plays a critical role in managing the key drivers of prediabetes.  

Active compounds:
Secoiroids (incl. Oleuropein)             ≥ 3.90%
Total anthocyanins                              ≥ 0.90%
Chromium                                             ≥ 150 ppm
Zinc                                                          ≥ 4500 ppm
Alpha-amylase inhibiting activity   ≥ 3500 AAIU/g

Composition: White kidney bean extract (Phaseolus Vulgaris L.), Green olive leaf extract (Olea europaea L.), Blackcurrant extract (Ribes nigrum L.), Zinc bisglycinate, Chromium picolinate.

Recommended daily dosage: 680 mg

Glyco680mg mitigates the molecular dysfunction

When carbohydrates are consumed, they are hydrolysed into glucose by enzymes such as alpha-amylase and alpha-glucosidase. Glyco680mg modulates this process through white kidney bean extract, which inhibits alpha-amylase, and blackcurrant anthocyanins, which inhibit alpha-glucosidase—effectively slowing the rate at which glucose enters the bloodstream. 

Once glucose is absorbed via intestinal transporters like SGLT1 and GLUT2, insulin secretion is triggered. At this stage, zinc plays a critical role by supporting insulin production, release, and sensitivity, ensuring an appropriate metabolic response and maintaining homeostasis. 

To further optimise glucose utilisation, chromium enhances insulin activity, improving the ability of cells to absorb glucose. Green olive polyphenols, particularly oleuropein, influence key transporters like GLUT2 and GLUT4, promoting efficient glucose uptake in muscle, liver, and adipose tissue. 

By providing these bioactive compounds at the right dose, Glyco680mg effectively addresses the risk factors contributing to type 2 diabetes, offering a natural, evidence-based approach to glucose management. 

Randomised, single-blind, crossover and placebo-controlled study.

Glyco680mg has been demonstrated to significantly reduce postprandial glucose levels.  

• Measure of postprandial glucose concentration of the subjects revealed a significant change in postprandial glucose kinetics between the placebo and Glyco680mg groups.

• The change in the area under the curve for postprandial glucose between the Glyco680mg group and placebo was significant, measuring the variations in glycaemia between pre- and postprandial conditions.

Glyco680mg is safe

No adverse events linked to Glyco680mg supplementation have been recorded.